Developer docs
API playgroundTry for free, no card

Search company profiles

Aposense

Full company profile

uuid002ca1p

Namestring
Aposense
Legal namestring
Aposense Ltd.
Websiteurl
aposense.com
Company typeenum
Private
Founded yearint
1996
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPetah Tiqva, Israel
HQ citystring
Petah Tiqva
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
intracellular drug delivery, molecular nano-motors, macromolecule therapeutics, biopharmaceutical platform, respiratory disease drugs
Industry2 codes
PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Drug Delivery Technology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing
TypeLicensing Royalties
Description

Licensing the MNM platform technology to pharmaceutical companies for use in drug development across multiple therapeutic areas.

interna.bio
2Research Collaborations
TypeProfessional Services
Description

Conducting research collaborations with pharmaceutical partners and institutions to advance MNM-based targeted delivery technologies.

interna.bio
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aposense (rebranded to Interna Therapeutics in November 2024) develops the Molecular Nano-Motors (MNMs) platform, a proprietary intracellular delivery technology that transports large molecules — including DNA, RNA, proteins, and peptides — into cell cytoplasm by harnessing membrane electrical forces intrinsic to all cell membranes. The company focuses initially on infectious and non-infectious respiratory diseases (with an intranasal COVID-19 drug in Phase I trials) and pursues licensing partnerships with pharmaceutical companies alongside independent research collaborations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Successfully completed Phase I clinical trial of intranasal COVID-19 drug
Product overview1 text field

Aposense (now rebranded as Interna Therapeutics after its November 2024 merger with SirVir) is a biopharmaceutical company developing the Molecular Nano-Motors (MNMs) platform — a universal drug delivery technology for intracellular delivery of macromolecule therapeutics including DNA, RNA, proteins, and peptides. The company is pursuing partnerships to license this technology to pharmaceutical companies while conducting independent research, with a current focus on infectious and non-infectious respiratory diseases. The MNM platform is the core technology, and the company has an intranasal COVID-19 drug candidate in clinical development.

Product and service2 records
1Molecular Nano-Motors (MNMs) Platform
CategoryDrug Delivery Technology Platform
Description

A novel intracellular delivery technology that uses molecular nano-motors powered by the electrical forces intrinsic to all cell membranes to transport large molecule therapeutics — DNA, RNA, proteins, peptides — into the cell cytoplasm. It features a universal attachment system adaptable to broad molecular cargoes and supports multiple administration methods. Intended to be licensed to pharmaceutical companies for integration into their drug development programs across multiple therapeutic areas.

2Intranasal COVID-19 Drug (MNM-based)
CategoryBiopharmaceutical Therapeutic Candidate
Description

Lead therapeutic candidate built on the MNM platform for intranasal delivery to treat COVID-19 / SARS-CoV-2, leveraging the platform's intracellular delivery and nasal administration capabilities. Phase I clinical trial successfully completed in May 2025; a Human Challenge Trial Agreement with the University of Oxford (March 2026) supports further development of an intranasal MNM-siRNA SARS-CoV-2 prophylaxis program.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Research collaboration to advance MNM-based targeted delivery technologies. This partnership leverages Daiichi Sankyo's pharmaceutical development capabilities with Interna Therapeutics' proprietary MNM platform for intracellular drug delivery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Human Challenge Trial Agreement to advance intranasal MNM-siRNA SARS-CoV-2 prophylaxis program. The collaboration advances novel prophylactic treatments for COVID-19 using the MNM platform for nasal drug delivery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

CureVac develops mRNA-based therapeutics using its proprietary RNActive platform and intranasal vaccine approaches. Comparable to Interna as an mRNA/infectious respiratory disease company with delivery expertise in nasal administration routes.

TypeDirect peer
Description

Genevant develops LNP and other lipid-based delivery systems for RNA therapeutics and licenses its platform to pharma and biotech partners. It is directly comparable to Interna as a non-viral nucleic acid delivery platform pursuing technology licensing economics.

TypeBroad incumbent
Description

BioNTech is a leading mRNA therapeutics company with proprietary LNP delivery capabilities used in its partnered COVID-19 vaccine. It is a broad incumbent in the nucleic acid delivery and intracellular delivery space.

TypeDirect peer
Description

Sirnaomics is a clinical-stage biopharma developing siRNA therapeutics with proprietary delivery platforms (PNP and GalNAc). It is directly comparable to Interna as a nucleic acid delivery platform company focused on intracellular delivery of macromolecules.

5Translate Bio (Sanofi)
TypeBroad incumbent
Description

Translate Bio developed an mRNA delivery platform and was acquired by Sanofi for ~$3.2B in 2021. While now part of a large incumbent, it historically mirrored Interna's strategy of licensing an mRNA delivery platform to a large pharma partner, making it a strong precedent comparable.

TypeDirect peer
Description

Arcturus is a clinical-stage mRNA medicines and siRNA delivery company with proprietary LNP and delivery platforms and partnerships with pharma (e.g., CSL, Janssen). It competes with Interna in the intracellular RNA delivery space and shares the licensing/partnership business model.

TypeOthers
Description

Precision Nanosystems (now part of Cytiva) provides nanoparticle delivery technology, instrumentation and services for nucleic acid therapeutics development. It is adjacent/infrastructure rather than a direct competitor, but operates in the same intracellular delivery ecosystem as Interna.

TypeDirect peer
Description

Acuitas is a Canadian specialist in lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, including mRNA and siRNA. It is a direct competitor to Interna's MNM platform as both companies license intracellular delivery modalities to large pharma partners (e.g., Pfizer/BioNTech for Acuitas).

TypeBroad incumbent
Description

Moderna is a leading mRNA technology platform company with proprietary LNP delivery and broad therapeutic pipeline. As a large established player, it overlaps with Interna's nucleic acid delivery and licensing opportunity set.

TypeDirect peer
Description

Wave Life Sciences develops stereopure nucleic acid therapeutics including siRNA and antisense oligonucleotides with platform-level delivery expertise. Comparable to Interna as an oligonucleotide-focused delivery and development company with partnered programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aposense

Biopharmaceutical Drug Delivery Technologyaposense.com

Aposense firmographics

Firmographics
Name
Aposense
Legal name
Aposense Ltd.
Website
https://aposense.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Aposense industry classification

Industry
Product category
Biopharmaceutical Drug Delivery Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Intracellular drug delivery
  • Molecular nano-motors
  • Macromolecule therapeutics
  • Biopharmaceutical platform
  • Respiratory disease drugs

Where Aposense is headquartered

Location

Headquarters

HQ city
Petah Tiqva
HQ country
Israel
HQ region
Middle East

Markets served

Aposense business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Technology Licensing: Licensing the MNM platform technology to pharmaceutical companies for use in drug development across multiple therapeutic areas.
  2. Research Collaborations: Conducting research collaborations with pharmaceutical partners and institutions to advance MNM-based targeted delivery technologies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Aposense product offering

Product offering

Core offering

Aposense (rebranded to Interna Therapeutics in November 2024) develops the Molecular Nano-Motors (MNMs) platform, a proprietary intracellular delivery technology that transports large molecules — including DNA, RNA, proteins, and peptides — into cell cytoplasm by harnessing membrane electrical forces intrinsic to all cell membranes. The company focuses initially on infectious and non-infectious respiratory diseases (with an intranasal COVID-19 drug in Phase I trials) and pursues licensing partnerships with pharmaceutical companies alongside independent research collaborations.

Product overview

Aposense (now rebranded as Interna Therapeutics after its November 2024 merger with SirVir) is a biopharmaceutical company developing the Molecular Nano-Motors (MNMs) platform — a universal drug delivery technology for intracellular delivery of macromolecule therapeutics including DNA, RNA, proteins, and peptides. The company is pursuing partnerships to license this technology to pharmaceutical companies while conducting independent research, with a current focus on infectious and non-infectious respiratory diseases. The MNM platform is the core technology, and the company has an intranasal COVID-19 drug candidate in clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Molecular Nano-Motors (MNMs) Platform A novel intracellular delivery technology that uses molecular nano-motors powered by the electrical forces intrinsic to all cell membranes to transport large molecule therapeutics — DNA, RNA, proteins, peptides — into the cell cytoplasm. It features a universal attachment system adaptable to broad molecular cargoes and supports multiple administration methods. Intended to be licensed to pharmaceutical companies for integration into their drug development programs across multiple therapeutic areas.
  • Intranasal COVID-19 Drug (MNM-based) Lead therapeutic candidate built on the MNM platform for intranasal delivery to treat COVID-19 / SARS-CoV-2, leveraging the platform's intracellular delivery and nasal administration capabilities. Phase I clinical trial successfully completed in May 2025; a Human Challenge Trial Agreement with the University of Oxford (March 2026) supports further development of an intranasal MNM-siRNA SARS-CoV-2 prophylaxis program.

Quantifiable outcome

  • Successfully completed Phase I clinical trial of intranasal COVID-19 drug

Companies that use Aposense

Customer profile

Segments2 records

Ideal customer profiles1 record

Aposense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Aposense partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Daiichi SankyocoreStrategic or Co-development Partner · 16 April 2026Research collaboration to advance MNM-based targeted delivery technologies. This partnership leverages Daiichi Sankyo's pharmaceutical development capabilities with Interna Therapeutics' proprietary MNM platform for intracellular drug delivery.
  • University of OxfordcoreStrategic or Co-development Partner · 23 March 2026Human Challenge Trial Agreement to advance intranasal MNM-siRNA SARS-CoV-2 prophylaxis program. The collaboration advances novel prophylactic treatments for COVID-19 using the MNM platform for nasal drug delivery.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Aposense competitors and assessment

Company assessment

Broad incumbents

  • CureVac: CureVac develops mRNA-based therapeutics using its proprietary RNActive platform and intranasal vaccine approaches. Comparable to Interna as an mRNA/infectious respiratory disease company with delivery expertise in nasal administration routes.
  • BioNTech: BioNTech is a leading mRNA therapeutics company with proprietary LNP delivery capabilities used in its partnered COVID-19 vaccine. It is a broad incumbent in the nucleic acid delivery and intracellular delivery space.
  • Translate Bio (Sanofi): Translate Bio developed an mRNA delivery platform and was acquired by Sanofi for ~$3.2B in 2021. While now part of a large incumbent, it historically mirrored Interna's strategy of licensing an mRNA delivery platform to a large pharma partner, making it a strong precedent comparable.
  • Moderna: Moderna is a leading mRNA technology platform company with proprietary LNP delivery and broad therapeutic pipeline. As a large established player, it overlaps with Interna's nucleic acid delivery and licensing opportunity set.

Direct peers

  • Genevant Sciences: Genevant develops LNP and other lipid-based delivery systems for RNA therapeutics and licenses its platform to pharma and biotech partners. It is directly comparable to Interna as a non-viral nucleic acid delivery platform pursuing technology licensing economics.
  • Sirnaomics: Sirnaomics is a clinical-stage biopharma developing siRNA therapeutics with proprietary delivery platforms (PNP and GalNAc). It is directly comparable to Interna as a nucleic acid delivery platform company focused on intracellular delivery of macromolecules.
  • Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines and siRNA delivery company with proprietary LNP and delivery platforms and partnerships with pharma (e.g., CSL, Janssen). It competes with Interna in the intracellular RNA delivery space and shares the licensing/partnership business model.
  • Acuitas Therapeutics: Acuitas is a Canadian specialist in lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, including mRNA and siRNA. It is a direct competitor to Interna's MNM platform as both companies license intracellular delivery modalities to large pharma partners (e.g., Pfizer/BioNTech for Acuitas).
  • Wave Life Sciences: Wave Life Sciences develops stereopure nucleic acid therapeutics including siRNA and antisense oligonucleotides with platform-level delivery expertise. Comparable to Interna as an oligonucleotide-focused delivery and development company with partnered programs.

Others

  • Precision Nanosystems (Cytiva): Precision Nanosystems (now part of Cytiva) provides nanoparticle delivery technology, instrumentation and services for nucleic acid therapeutics development. It is adjacent/infrastructure rather than a direct competitor, but operates in the same intracellular delivery ecosystem as Interna.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Aposense social profiles

Digital presence

Aposense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aposense leadership team

Management profile

Number of profiles

Profiles8 records

Aposense funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aposense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aposense

What does Aposense do?

Aposense (rebranded to Interna Therapeutics in November 2024) develops the Molecular Nano-Motors (MNMs) platform, a proprietary intracellular delivery technology that transports large molecules — including DNA, RNA, proteins, and peptides — into cell cytoplasm by harnessing membrane electrical forces intrinsic to all cell membranes. The company focuses initially on infectious and non-infectious respiratory diseases (with an intranasal COVID-19 drug in Phase I trials) and pursues licensing partnerships with pharmaceutical companies alongside independent research collaborations.

Is Aposense a public or private company?

Aposense is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aposense founded?

Aposense was founded in 1996. It employs 11 to 50 people.

Where is Aposense based?

Aposense is headquartered in Petah Tiqva, Israel, in the Middle East region.

How does Aposense make money?

Two revenue lines are on record. Technology Licensing is the primary driver. The others are research Collaborations.

Who are Aposense's main competitors?

Broad incumbents on record are CureVac, BioNTech, Translate Bio (Sanofi) and Moderna. Direct peers are Genevant Sciences, Sirnaomics, Arcturus Therapeutics, Acuitas Therapeutics and Wave Life Sciences. Precision Nanosystems (Cytiva) is listed as an others.

Does Aposense have an API?

No public API is recorded for Aposense.

What industry is Aposense in?

Aposense's product category is Biopharmaceutical Drug Delivery Technology. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods), with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaBIOAF: New Funding & Research Collaborations Expand xB3 Opportunities - BIOASIS TECHNOLOGIES INC by BioasBioasis Technologies Inc. reported first quarter fiscal year 2022 operational and financial results for the period ending May 31, 2021, posting total operating expenses of CA$789,000 and a net loss of $541,000, while expanding its xB3 blood-brain barrier technology platform through two new research collaborations with Aposense and Oxyrane UK Ltd. The company also secured a CA$10 million convertible security funding agreement with Lind Global Macro Fund, closing the initial $3 million tranche in June 2021, and announced positive preclinical results showing delayed onset and reduced clinical symptom scores in a rodent multiple sclerosis model using xB3-IL-1RA. Bioasis appointed two senior executives including a new CFO and Preclinical Program Manager, and published peer-reviewed research validating the xB3 platform's ability to deliver siRNA and other payloads across the blood-brain barrier.GlobeNewswirePROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUGProcessa Pharmaceuticals announced a licensing agreement with Aposense to develop and commercialize ATT-11T, a next-generation irinotecan pro-drug. Aposense will receive shares worth $2.5M and up to $125M in milestones, plus 7% royalties. The deal is subject to financing and NASDAQ/NYSE listing.NatureApo-Si: a gene delivery platformAposense's Apo-Si platform uses Molecular NanoMotors to harness the intramembrane electric field for delivering genetic drugs like siRNA across cell membranes. The platform has completed core development, including in vitro and in vivo delivery and gene silencing studies. It may become a unified industry standard for transmembrane delivery of genetic drugs.GlobeNewswireAposense Announces Successful Completion of IPOAposense completed its IPO on the Tel Aviv Stock Exchange, listing shares under APOS on June 9. The deal valued the company at over NIS 900 million (US$230 million) post-IPO, with shares trading at NIS 10.50. The company raised over US$24 million, including US$16 million from the IPO and US$8 million from a private placement.GlobeNewswireAposense(R) ML-10 Technology for Molecular Imaging of Apoptosis to Be Used by GSK in Experimental Oncology StudiesAposense Ltd. announced a collaboration with GlaxoSmithKline to evaluate its PET tracer ML-10 for monitoring drug activity in cancer therapy clinical trials. The two-year nonexclusive agreement aims to accelerate oncology drug development, with financial terms undisclosed.GlobeNewswireNST NeuroSurvival Technologies Completes $13.3 Million Financing, Changes Name to Aposense Ltd.NST NeuroSurvival Technologies completed a $13.3 million financing and changed its name to Aposense Ltd. The two-part financing raised $6 million in September 2007 and $7.3 million now, with existing shareholders participating. The funds will support Phase 3 clinical trials of its ML-10 compound for apoptosis imaging.